Healthesystems is attending the NCCI Annual Insights Symposium, which brings together senior thought leaders in workers' comp.
Healthesystems is exhibiting at the PA Workers’ Comp Conference, an educational seminar for professionals within the field of PA workers’ comp.
Approval Date: Apr 2025
Indicated for the acute treatment of migraine with or without aura, administered via a unique nasal delivery device
Approval Date: Mar 2025
Indicated for the treatment of hypertension, stroke risk reduction in patients with hypertension and left ventricular hypertrophy, and diabetic neuropathy in certain type 2 diabetes patients with hypertension
Approval Date: Mar 2025
A biosimilar to Acterma®, this autoimmune drug has received an additional indication for the treatment of COVID-19 in hospitalized patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)
Approval Date: Jan 2025
A combination NSAID and triptan drug indicated for the acute treatment of migraine with or without aura
Approval Date: Jan 2025
An NMDA receptor antagonist, this drug is now indicated for use as a monotherapy for treatment-resistant depression (TRD). Spravato originally required conjunctive use with an oral antidepressant for (TRD)
Approval Date: Jan 2025
A biosimilar to Acterma, this drug is indicated for the treatment of rheumatoid arthritis, giant cell arthritis, and COVID-19 in hospitalized patients receiving supplemental oxygen and corticosteroids
Approval Date: Jan 2025
A novel, first-in-class, non-opioid analgesic indicated for the treatment of moderate to severe acute pain. Journavx targets pain-signaling pathways involving sodium channels and has not been studied for use beyond 14 days
Approval Date: Dec 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the once-daily treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Dec 2024
A biosimilar to Stelara®, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis
Approval Date: Dec 2024
An SSRI indicated for the treatment of major depressive disorder (MDD)
Approval Date: Nov 2024
A GLP-1 receptor agonist, this first-time generic is indicated for the treatment of type 2 diabetes, in conjunction with diet and exercise
Approval Date: Sep 2024
A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis
Approval Date: Aug 2024
Indicated for the treatment of opioid-induced constipation
Approval Date: Aug 2024
An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.
Approval Date: Aug 2024
Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults
